Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 15Other solid neoplasm 15Genitourinary 3Gastrointestinal 3Dermatologic 2Head & Neck 1Gynecologic 1Breast 1

Conditions

Melanoma 273Carcinoma, Non-Small-Cell Lung 49Carcinoma, Renal Cell 37Uveal Melanoma 23Skin Neoplasms 23Neoplasm Metastasis 23Colorectal Neoplasms 22Carcinoma, Transitional Cell 20Carcinoma, Merkel Cell 20Squamous Cell Carcinoma of Head and Neck 19Neoplasms 18Lung Neoplasms 17Carcinoma, Hepatocellular 16Brain Neoplasms 16Triple Negative Breast Neoplasms 14Uterine Cervical Neoplasms 13Ovarian Neoplasms 13Stomach Neoplasms 12Urinary Bladder Neoplasms 10Small Cell Lung Carcinoma 10Head and Neck Neoplasms 9Lymphoma 8Carcinoma, Basal Cell 8Pancreatic Neoplasms 7Esophageal Neoplasms 7Breast Neoplasms 7Kidney Neoplasms 6Sarcoma 5Prostatic Neoplasms 5Hodgkin Disease 5

Interventions

pembrolizumab 2atezolizumab 2Nivolumab 2entinostat 1durvalumab 1cemiplimab 1bemcentinib 1avelumab 1Polymerase Chain Reaction 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Ipilimumab 1Interleukin-2 1In Situ Hybridization, Fluorescence 1Immunoglobulin G 1Immunoenzyme Techniques 1Immune Checkpoint Inhibitors 1Gene Expression Profiling 1Flow Cytometry 1Fentanyl 1Etoposide 1Docetaxel 1Disulfides 1Cyclophosphamide 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Nivolumab × Dermatologic × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡